Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non–small-cell lung cancer: a phase III trial

GV Scagliotti, M Krzakowski, A Szczesna… - Journal of clinical …, 2012 - ascopubs.org
Purpose Sunitinib plus erlotinib may enhance antitumor activity compared with either agent
alone in non–small-cell lung cancer (NSCLC), based on the importance of the signaling …
被引用次数：243 相关文章

Sunitinib Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer: A Phase III Trial

GV Scagliotti, M Krzakowski, A Szczesna… - Journal of Clinical …, 2012 - cir.nii.ac.jp
< jats: sec>< jats: title> Purpose</jats: title>< jats: p> Sunitinib plus erlotinib may enhance
antitumor activity compared with either agent alone in non–small-cell lung cancer (NSCLC) …

Sunitinib Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer: A Phase III Trial.

GV Scagliotti, M Krzakowski, A Szczesna… - JOURNAL OF …, 2012 - iris.unito.it
PURPOSE Sunitinib plus erlotinib may enhance antitumor activity compared with either
agent alone in non-small-cell lung cancer (NSCLC), based on the importance of the …

[引用][C] Sunitinib Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Previously Treated Advanced Non―Small-Cell Lung Cancer: A Phase III Trial

GV SCAGLIOTTI, M KRZAKOWSKI… - Journal of clinical …, 2012 - pascal-francis.inist.fr
Sunitinib Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Previously Treated Advanced
Non―Small-Cell Lung Cancer: A Phase III Trial CNRS Inist Pascal-Francis CNRS Pascal and …

Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: A phase III trial

GV Scagliotti, M Krzakowski, A Szczesna… - Journal of Clinical …, 2012 - profiles.wustl.edu
Purpose: Sunitinib plus erlotinib may enhance antitumor activity compared with either agent
alone in non-small-cell lung cancer (NSCLC), based on the importance of the signaling …

[引用][C] Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: A phase III trial

GV Scagliotti, M Krzakowski, A Szczesna… - Journal of Clinical …, 2012 - elibrary.ru

Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: A phase III trial

GV Scagliotti, M Krzakowski, A Szczesna, J Strausz… - 2012 - cmuir.cmu.ac.th
Purpose: Sunitinib plus erlotinib may enhance antitumor activity compared with either agent
alone in non-small-cell lung cancer (NSCLC), based on the importance of the signaling …

Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: a phase III trial

GV Scagliotti, M Krzakowski… - Journal of clinical …, 2012 - pubmed.ncbi.nlm.nih.gov
Purpose Sunitinib plus erlotinib may enhance antitumor activity compared with either agent
alone in non-small-cell lung cancer (NSCLC), based on the importance of the signaling …

Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: a phase III trial.

GV Scagliotti, M Krzakowski, A Szczesna… - Journal of Clinical …, 2012 - europepmc.org
Purpose Sunitinib plus erlotinib may enhance antitumor activity compared with either agent
alone in non-small-cell lung cancer (NSCLC), based on the importance of the signaling …

[引用][C] Sunitinib Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Previously Treated Advanced Non―Small-Cell Lung Cancer: A Phase III Trial

GV SCAGLIOTTI… - Journal of …, 2012 - American Society of Clinical …